Raquel Izumi

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

John C. Byrd, Peter Hillmen, Paolo Ghia et al. · Journal of Clinical Oncology · 2021 · 635 citations · Full text

Medicine, Oncology, Pharmacology +10

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 612 citations · Full text

Medicine, Hematology, Pharmacology +10

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Susan O’Brien, Richard R. Furman, Steven Coutré et al. · The Lancet Oncology · 2013 · 465 citations

Medicine, Immunology, Oncology +10